#CTAD26: Priavoid’s amyloid-detangling pill PRI-002 fails Phase 2 study in Alzheimer’s
BOSTON — For nearly a decade, the German biotech startup Priavoid has been working on a pill to break up small clumps of amyloid proteins that accumulate in the brains of people with Alzheimer’s disease. Now ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.